This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OxyContin (reformulated)

Purdue Pharma LP

Drug Names(s): extended release oxycodone hydrochloride, OxyContin Neo

Description: OxyContin, an extended release opioid analgesic, is a reformulated version of OxyContin. It was designed to make the tablet more difficult to manipulate for the purpose of intentional misuse and abuse.

Deal Structure: Shionogi & Co. and Mundipharma
In November 2013, Shionogi & Company announced that it has entered into a license agreement with Mundipharma for the exclusive rights to develop, manufacture and commercialize, for the treatment of pain, OxyContin Neo tablets (tamper-resistant OxyContin tablets) and Oxycodone/Naloxone Combination tablets (brand name in overseas; Targin tablets or Targinact tablets) in Japan. Under the terms of the agreement, Shionogi will pay Mundipharma an upfront license payment and development and sales milestones, as well as royalties based on net sales of the products in Japan.

Partners: Shionogi & Co. Ltd. Mundipharma International Limited

OxyContin (reformulated) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug